よむ、つかう、まなぶ。
【参考資料２－３】抗微生物薬適正使用の手引き 第四版（案）薬剤耐性菌感染症の抗菌薬適正使用編 (96 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_64503.html |
| 出典情報 | 厚生科学審議会 感染症部会（第99回 10／21）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
抗微生物薬適正使用の手引き
第四版
薬剤耐性菌感染症の抗菌薬適正使用編
1
2
3
120. Chuang YC, et al. Effectiveness of tigecycline-based versus colistin- based therapy for
treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a
critical setting: a matched cohort analysis. BMC Infect Dis. 2014. 14:102.
4
5
6
121. Kengkla K, et al. Comparative efficacy and safety of treatment options for MDR and
XDR Acinetobacter baumannii infections: a systematic review and network metaanalysis. J Antimicrob Chemother. 2018. 73(1):22-32.
7
8
122. Government of South Australia. Staphylococcus aureus Bacteraemia Management
Clinical Guideline Version 2.0. 2023.
9
10
11
123. Kwon KH, et al. Colistin treatment in carbapenem-resistant Acinetobacter baumannii
pneumonia patients: Incidence of nephrotoxicity and outcomes. Int J Antimicrob Agents.
2015. 45(6):605-609.
12
13
14
15
124. Liu J, et al. Comparative efficacy and safety of combination therapy with high-dose
sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and
extensively drug-resistant Acinetobacter baumannii infections: A systematic review and
network meta-analysis. J Glob Antimicrob Resist. 2021. 24:136-147.
16
17
18
125. Sadyrbaeva-Dolgova S, et al. Incidence of nephrotoxicity associated with intravenous
colistimethate sodium administration for the treatment of multidrug-resistant gramnegative bacterial infections. Sci Rep. 2022. 12(1):15261.
19
20
21
126. Falcone M, et al. Cefiderocol- Compared to Colistin-Based Regimens for the Treatment
of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii.
Antimicrob Agents Chemother. 2022. 66(5):e0214221.
22
23
24
25
127. Russo A, et al. Efficacy of cefiderocol- vs colistin-containing regimen for treatment of
bacteraemic ventilator-associated pneumonia caused by carbapenem-resistant
Acinetobacter baumannii in patients with COVID-19. Int J Antimicrob Agents. 2023.
62(1):106825.
26
27
28
128. Pascale R, et al. Cefiderocol treatment for carbapenem-resistant Acinetobacter
baumannii infection in the ICU during the COVID-19 pandemic: a multicentre cohort
study. JAC Antimicrob Resist. 2021. 3(4):dlab174.
29
30
31
129. Durante-Mangoni E, et al. Colistin and rifampicin compared with colistin alone for the
treatment of serious infections due to extensively drug-resistant Acinetobacter
baumannii: a multicenter, randomized clinical trial. Clin Infect Dis. 2013. 57(3):349-358.
32
33
34
130. Park HJ, et al. Colistin monotherapy versus colistin/rifampicin combination therapy in
pneumonia caused by colistin-resistant Acinetobacter baumannii: A randomised
controlled trial. J Glob Antimicrob Resist. 2019. 17:66-71.
35
36
37
131. Aydemir H, et al. Colistin vs. the combination of colistin and rifampicin for the treatment
of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia.
Epidemiol Infect. 2013. 141(6):1214-1222.
38
39
40
132. Sirijatuphat R, et al. Preliminary study of colistin versus colistin plus fosfomycin for
treatment of carbapenem-resistant Acinetobacter baumannii infections. Antimicrob
Agents Chemother. 2014. 58(9):5598-5601.
41
42
43
133. Makris D, et al. Colistin versus Colistin Combined with Ampicillin-Sulbactam for
Multiresistant Acinetobacter baumannii Ventilator-associated Pneumonia Treatment: An
Open-label Prospective Study. Indian J Crit Care Med. 2018. 22(2):67-77.
44
45
134. Perez F, et al. Antibiotic-resistant gram-negative bacterial infections in patients with
cancer. Clin Infect Dis. 2014. 59 Suppl 5:S335-9.
96
第四版
薬剤耐性菌感染症の抗菌薬適正使用編
1
2
3
120. Chuang YC, et al. Effectiveness of tigecycline-based versus colistin- based therapy for
treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a
critical setting: a matched cohort analysis. BMC Infect Dis. 2014. 14:102.
4
5
6
121. Kengkla K, et al. Comparative efficacy and safety of treatment options for MDR and
XDR Acinetobacter baumannii infections: a systematic review and network metaanalysis. J Antimicrob Chemother. 2018. 73(1):22-32.
7
8
122. Government of South Australia. Staphylococcus aureus Bacteraemia Management
Clinical Guideline Version 2.0. 2023.
9
10
11
123. Kwon KH, et al. Colistin treatment in carbapenem-resistant Acinetobacter baumannii
pneumonia patients: Incidence of nephrotoxicity and outcomes. Int J Antimicrob Agents.
2015. 45(6):605-609.
12
13
14
15
124. Liu J, et al. Comparative efficacy and safety of combination therapy with high-dose
sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and
extensively drug-resistant Acinetobacter baumannii infections: A systematic review and
network meta-analysis. J Glob Antimicrob Resist. 2021. 24:136-147.
16
17
18
125. Sadyrbaeva-Dolgova S, et al. Incidence of nephrotoxicity associated with intravenous
colistimethate sodium administration for the treatment of multidrug-resistant gramnegative bacterial infections. Sci Rep. 2022. 12(1):15261.
19
20
21
126. Falcone M, et al. Cefiderocol- Compared to Colistin-Based Regimens for the Treatment
of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii.
Antimicrob Agents Chemother. 2022. 66(5):e0214221.
22
23
24
25
127. Russo A, et al. Efficacy of cefiderocol- vs colistin-containing regimen for treatment of
bacteraemic ventilator-associated pneumonia caused by carbapenem-resistant
Acinetobacter baumannii in patients with COVID-19. Int J Antimicrob Agents. 2023.
62(1):106825.
26
27
28
128. Pascale R, et al. Cefiderocol treatment for carbapenem-resistant Acinetobacter
baumannii infection in the ICU during the COVID-19 pandemic: a multicentre cohort
study. JAC Antimicrob Resist. 2021. 3(4):dlab174.
29
30
31
129. Durante-Mangoni E, et al. Colistin and rifampicin compared with colistin alone for the
treatment of serious infections due to extensively drug-resistant Acinetobacter
baumannii: a multicenter, randomized clinical trial. Clin Infect Dis. 2013. 57(3):349-358.
32
33
34
130. Park HJ, et al. Colistin monotherapy versus colistin/rifampicin combination therapy in
pneumonia caused by colistin-resistant Acinetobacter baumannii: A randomised
controlled trial. J Glob Antimicrob Resist. 2019. 17:66-71.
35
36
37
131. Aydemir H, et al. Colistin vs. the combination of colistin and rifampicin for the treatment
of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia.
Epidemiol Infect. 2013. 141(6):1214-1222.
38
39
40
132. Sirijatuphat R, et al. Preliminary study of colistin versus colistin plus fosfomycin for
treatment of carbapenem-resistant Acinetobacter baumannii infections. Antimicrob
Agents Chemother. 2014. 58(9):5598-5601.
41
42
43
133. Makris D, et al. Colistin versus Colistin Combined with Ampicillin-Sulbactam for
Multiresistant Acinetobacter baumannii Ventilator-associated Pneumonia Treatment: An
Open-label Prospective Study. Indian J Crit Care Med. 2018. 22(2):67-77.
44
45
134. Perez F, et al. Antibiotic-resistant gram-negative bacterial infections in patients with
cancer. Clin Infect Dis. 2014. 59 Suppl 5:S335-9.
96